Mark P Saunders - JoVE Visualize

Showing results (31-40 of 55) with videos related to

Pageof 6

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)Paulo M Hoff, Andreas Hochhaus, Bernhard C Pestalozzi, et al.

Clinical Colorectal Cancer|December 13, 2025

Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN StudyRosie Maye Solomon, Robert D Morgan, Laura Horsley, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2020

Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of "Stemness" Programs and Local InflammationJorge Barriuso, Raghavendar T Nagaraju, Shreya Belgamwar, et al.

European Journal of Cancer (Oxford, England : 1990)|March 31, 2015

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trialGuillem Argilés, Mark P Saunders, Fernando Rivera, et al.

The Lancet. Oncology|April 13, 2013

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.

British Journal of Cancer|November 9, 2022

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancerDavid J Propper, Fangfei Gao, Mark P Saunders, et al.

Clinical Colorectal Cancer|March 26, 2023

SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)Mark P Saunders, Rohan Iype, Caroline Kelly, et al.

Astrobiology|February 6, 2016

Planetary Protection and Mars Special Regions--A Suggestion for Updating the DefinitionPetra Rettberg, Alexandre M Anesio, Victor R Baker, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.

Lancet (London, England)|June 14, 2025

Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trialSheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.

Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:

Pageof 6

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)Paulo M Hoff, Andreas Hochhaus, Bernhard C Pestalozzi, et al.

Clinical Colorectal Cancer|December 13, 2025

Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN StudyRosie Maye Solomon, Robert D Morgan, Laura Horsley, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2020

Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of "Stemness" Programs and Local InflammationJorge Barriuso, Raghavendar T Nagaraju, Shreya Belgamwar, et al.

European Journal of Cancer (Oxford, England : 1990)|March 31, 2015

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trialGuillem Argilés, Mark P Saunders, Fernando Rivera, et al.

The Lancet. Oncology|April 13, 2013

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.

British Journal of Cancer|November 9, 2022

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancerDavid J Propper, Fangfei Gao, Mark P Saunders, et al.

Clinical Colorectal Cancer|March 26, 2023

SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)Mark P Saunders, Rohan Iype, Caroline Kelly, et al.

Astrobiology|February 6, 2016

Planetary Protection and Mars Special Regions--A Suggestion for Updating the DefinitionPetra Rettberg, Alexandre M Anesio, Victor R Baker, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.

Lancet (London, England)|June 14, 2025

Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trialSheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.

Pageof 6